All News

Article

Putting IL17i into ‘focus’ for SpA-associated uveitis

Janet Pope, MD, MPH, FRCPC Jun 12, 2025

The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than golimumab and certolizumab pegol.

Other data have emerged for JAKi and IL17i, with respect to acute anterior uveitis.

Article

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA Jun 12, 2025

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.

#EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib were maintained through to Week 104. Those who switched from PBO at WK48 to UPA + ELSU also improved. No VTE or MACE. Is add-on ELSU really needed? @RheumNow https://t.co/x8NbAtsHh0

https://x.com/Yuz6Yusof/status/1933198167765586162/photo/1

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.

Live Daily Eular 2025 Recap Day 1 https://t.co/dLV83VcGuC

Dr. John Cush

Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI

https://x.com/drdavidliew/status/1932790928185700426/photo/1

#neuromodulation in #rheumatoid #arthritis What is it? 👇 Autonomic & immune system interaction Who seeks this Rx? desperate pts w pain No Rx left Interested in technology #EULAR2025 @RheumNow @eular_org #D2T #RA https://t.co/XWWFiUK6Em

#vagal & #splenic #nerves most studied In #immune #system interaction #PNS can detect #inflammation use in #D2T #RA w active disease ? Key factors in #neurostimulation - many #EULAR2025 @RheumNow @eular_org #D2T in #RA session https://t.co/tCgpGtI5z2

The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases? A thread 🧵👇🏼 @RheumNow #EULAR2025 https://t.co/KLZN9MvcFy

https://x.com/AurelieRheumo/status/1933167023678464465/photo/1

Interesting debate today #EULAR2025 about medical cannabis - where relative harms have come up. Would you rather be addicted to prescription opioids or recreational cannabis? (not going to argue about cannabis addiction - let’s say social impact is equal) @RheumNow

#Vagal #nerve #stimulation Hand held device #BDMARD failure Plausible - improved pro inflammatory cytokines wears off benefit if stopped Attenuates in ~half over yrs Open label uncontrolled @RheumNow @eular_org #EULAR2025 Session D2T-RA https://t.co/98K5gwasHv

#RCT of #vagus #nerve #stimulation in #bDMARD-IR #RA Pts RESSET RCT +RA #RCT w #VNS But low response with stat significance ACR20 1/4 sham vs 1/3 VNS Would add on to new SoC? 🤔 #EULAR2025 @RheumNow #eular_org #D2T- RA-session https://t.co/tR1pLPBr74

So we used to get taught about bimodal age distribution of RA onset - young people and old people. Actually, it’s early middle age where RA diagnoses have now grown globally over 30y - right in peak productivity Global Burden of Disease data #EULAR2025 OP0240-HPR @RheumNow https://t.co/8yyrex00yy

https://x.com/drdavidliew/status/1933176266838217116/photo/1

Prédiction of PsA from PsO. Stockholm cohort, n=672): •PsA incidence 21.1/1000 PY. •AUC 0.80 for both referral and prognostic models. •Predictors: HLA-B27, uveitis, enthesial pain, TJC, hsCRP, BMI, SAA, GlycA. •Early identification feasible. Abstract OP0178 @RheumNow https://t.co/dxdChN6VZy

https://x.com/synovialjoints/status/1933178050859962663/photo/1

Do the sites of clinical onset of PsA (i.e., swelling) correspond to those that, at the time of enrollment in the study, showed evidence of joint tenderness and/or ultrasound-detected alterations compatible with inflammation? Of 28 incident PsA cases, 68% had prior subclinical https://t.co/rAZJU6Va5x

https://x.com/synovialjoints/status/1933179112287264951/photo/1

Even after having things laid out in a great debate, rheumatologists remain unconvinced by medical cannabis #EULAR2025 @RheumNow https://t.co/xMTvngS5N1

https://x.com/drdavidliew/status/1933179631160742222/photo/1

Study on the HLAs associated with the occurrence and course of acute/tender dactylitis in PsA patients. Acute dactylitis genetics: •HLA-B27 (OR 1.71), HLA-C12 (OR 1.43), B38/C12 & B27/C02 haplotypes. •Resolution faster on b/tsDMARDs (HR 1.67); unaffected by HLA. Abstract

cool stuff at #EULAR2025 RESET #RCT - #vagal #nerve #stimulation #VNS vs sham in #RA w 1or >1 #bDMARD-IR N=242 D/C bDMARD, on #csDMARD #RA 12 yrs, 10SJC 12TJC 2.6 b/tsDMARD failure Wk12 EULAR good/mod response 61v 42% Sham▶️goes VNS ✅data= @RheumNow @eular_org abst#OP190

Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/qi0qHPd06j

#polyrefractory #RA = failed all classes in #rheumatoid #arthritis +inflammatory #arthritis Longer disease duration Late RA Rx +power Doppler in POCUS ⬆️no refractory BMI Fibromyalgia - pain ⬇️SJC, less DAS , rapid X-ray progression #EULAR2025 @RheumNow #D2T #RA https://t.co/1sPwf3Qa3m

Topics

All News

Putting IL17i into ‘focus’ for SpA-associated uveitis

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Do you get our email newsletter?